For Project ACTT, a population of Canadian women with metastatic breast cancer were tested using a liquid biopsy gene panel during the COVID-19 pandemic to identify biomarkers that could match them with targeted therapies. Certain mutations have been known to respond better to some targeted therapies. Results of this study will be presented outlining how earlier use of targeted therapies improve outcomes through the use of liquid biopsy.
Benjamin L. Furman; Ebru Baran; Sonal Brahmbhatt; Betty Chan; Ka Mun Nip; Adrian Kense; Brenda Murphy; Vincent Funari; David G. Huntsman; Ruth Miller; Melissa K. McConechy
The new DNA-based NGS molecular classifier (ProMisE NGS) was used to determine the molecular subtype in 164endometrial cancer (ECs) previously classified with ProMisE. ProMisE is a multi-test platform; next generation sequencing (NGS) and immunohistochemistry (IHC) for (EC) molecular classification.
Reliable molecular subtyping can be obtained from first diagnostic biopsy using a single-test NGS targeted assay.
Amy Jamieson a 1, Melissa K. McConechy b 1, Amy Lum c, Samuel Leung c, Emily F. Thompson c, Janine Senz c, Aline Talhouk c, David G. Huntsman b c, Ali Bashashati d e, C. Blake Gilks e, Jessica N. McAlpine a
Dr. Natasha Leighl and her team at University Health Network published their pilot data on using liquid biopsy testing earlier in a lung cancer patient's journey. Usually, 1) patients with severe enough symptoms of respiratory issues will be imaged. 2) Images and clinical presentation of potential lung cancer will be referred for biopsy. 3) Tissue biopsy will be used to diagnose lung cancer (i.e. pathological diagnosis). 4) Biomarker testing is done on tissue. 5) Patients receive targeted therapy if druggable mutation is found. In Dr. Leighl's study, her team used Follow It through our testing program after step 2. This shortened time from referral to treatment by half (60 days to 30 days).
Congratulations to everyone, especially to the clinical team for continuing to process samples day-in and day-out. This study is an example of ICH having an immediate impact on patients and having long-term effects on cancer care.
Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, Corke L, Waddell TK, Yasufuku K, Donahoe LL, Pierre A, Le LW, Ghumman N, Liu G, Shepherd FA, Bradbury P, Sacher A, Stockley T, Pal P, Rogalla P, Tsao MS, Leighl NB.
Melissa K. McConechy; Amy Jamieson; Amy Lum; Samuel Leung; Adrian Kense; Sonal Brahmbhatt; Ka Mun Nip; Ebru Baran; Dilmi Perera; Kurt Yakimovich; Ruth Miller; C. Blake Gilks; David Huntsman; Jessica N. McAlpine
Dilmi Perera; Sahand Khakabi; Ka Mun Nip; Sonal Brahmbatt; Adrian Kense; Kevin Tam; David Mulder; Melissa McConechy; David Huntsman; Ruth Miller; Rosalía Aguirre-Hernández
Emily F. Thompson, Richard W.C. Wong, Giorgia Trevisan, Basile Tessier-Cloutier, Noorah Almadani, Julia Chen, Angela Cheng, Anthony Karnezis, Melissa K. McConechy, Amy Lum, Janine Senz, Jessica N. McAlpine, David G. Huntsman, Blake Gilks, Amy Jamieson, Lynn N. Hoang
Service of Anatomic Pathology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec City, QC G1V 4G5, Canada 2Research Center, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec City, QC G1V 4G5, Canada 3Service of Respirology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec City, QC G1V 4G5, Canada
Amy Jamieson, Jutta Huvila, Derek Chiu, Emily F. Thompson, Stephanie Scott, Shannon Salvador, Danielle Vicus, Limor Helpman, Walter Gotlieb, Sarah Kean, Vanessa Samouelian, Martin Köbel, Mary Kinloch, Carlos Parra-Harran, Saul Offman, Katherine Grondin, Julie Irving, Amy Lum, Janine Senz, Samuel Leung, Melissa K. McConechy, Marie Plante, Stefan Kommoss, David G. Huntsman, Aline Talhouk, C. Blake Gilks, Jessica N. McAlpine
Jamieson A, Huvila J, Thompson EF, Leung S, Chiu D, Lum A, McConechy M, Grondin K, Aguirre-Hernandez R, Salvador S, Kean S, Samouelian V, Gougeon F, Azordegan N, Lytwyn A, Parra-Herran C, Offman S, Gotlieb W, Irving J, Kinloch M, Helpman L, Scott SA, Vicus D, Plante M, Huntsman DG, Gilks CB, Talhouk A, McAlpine JN
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
Project ACTT (Access to Cancer Testing and Treatment) in Response to COVID-19 was a joint effort led by Imagia Canexia Health and supported by Digital Supercluster and partner institutions.
The theme for this year’s World Cancer Day is Close the Care Gap. Health equity is a pillar of our work at Imagia Canexia Health. So today our Chief Medical Officer, Dr. David Huntsman, is opening the conversation to showcase how our community-centered approach to cancer care is improving access to genomic-driven cancer care for all.
